Results 161 to 170 of about 96,199 (216)

The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation. [PDF]

Bone Marrow Transplant
Franke GN, Ussmann J, Backhaus D, Nicolay NH, Kuhnt T, Nägler F, Jendro J, Vučinić V, Herling M, Schetschorke B, Herling C, Weibl S, Platzbecker U, Metzeler KH, Schwind S, Jentzsch M.   +15 more
europepmc   +1 more source

Cystatin C-based eGFR better predicts renal vancomycin clearance than creatinine-based eGFR in patients with allogeneic stem cell transplantation. [PDF]

Clin Pharmacol Ther
Wansing EA, Wicha SG, Bannas P, Heitkamp A, Dadkhah A, Kröger NM, Molwitz I, Langebrake C.   +7 more
europepmc   +1 more source

Graft-Versus-Leukemia Effect in the Management of Isolated Pancreatic Granulocytic Sarcoma Following Allogeneic Stem Cell Transplantation. [PDF]

Cureus
Kurt R, Aydin Y, Kalayoglu Besisik S.
europepmc   +1 more source

Thyroid Storm Following Alemtuzumab-based Allogeneic Stem Cell Transplantation: A Case Report and Literature Review. [PDF]

Intern Med
Saigusa S, Uchino K, Seki H, Sugita Y, Isaji Y, Iida Y, Shinohara S, Horio T, Murakami S, Mizuno S, Ikegame K, Hanamura I, Mokuno J, Takagi J, Hirano D, Iida H, Nakao S, Takami A.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Allogeneic Stem Cell Transplantation

Transplantation Proceedings, 2005
Allogeneic stem cell transplantation (HSCT) requires the harvest of an adequate number of stem cells (SC) from a histocompatible donor and their infusion into a patient following a conditioning regimen. During the past 35 years, the role of HSCT has changed from an experimental procedure for terminally ill patients to a curative treatment.
BOSI, ALBERTO, BARTOLOZZI B, GUIDI S.
openaire   +3 more sources

Innovations in allogeneic stem-cell transplantation

Seminars in Hematology, 2000
Allogeneic bone marrow transplantation (BMT) is associated with prolonged periods of neutropenia and thrombocytopenia, which can lead to severe infections and bleeding complications. Transplantation-related side effects might be ameliorated by use of cytokine-mobilized peripheral blood progenitor cells (PBPC) Instead of bone marrow.
J F, DiPersio, H, Khoury, J, Haug, R, Vij, D R, Adkins, L T, Goodnough, R A, Brown   +6 more
openaire   +2 more sources

Allogeneic blood stem cell transplantation

European Journal of Cancer, 2009
The development of haematopoietic blood stem cell transplantation after World War II was stimulated by the concept of having an efficient treatment against irradiation damage after the military use of nuclear weapons and after accidents in nuclear plants.
Gerhard, Ehninger, Martin, Bornhäuser
openaire   +2 more sources

Allogeneic stem-cell transplantation for myelofibrosis

Current Opinion in Hematology, 2017
Purpose of review Allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only curative therapy for myelofibrosis. The number of HSCTs performed for this indication has been steadily increasing over the past years, even after the approval of the Janus kinase (JAK) inhibitor, ruxolitinib.
Noa, Lavi, Jacob M, Rowe, Tsila, Zuckerman   +2 more
openaire   +2 more sources

Allogeneic Hematopoietic Stem Cell Transplantation

Therapeutic Apheresis and Dialysis, 2003
Abstract: More than 30 years have passed since the first clinical application of allogeneic bone marrow transplantation to treat hematological diseases. In recent years, the availability of peripheral blood and cord blood as additional sources of stem cells other than bone marrow has expanded the applicability of hematopoietic stem cell transplantation.
Shunro, Kai, Hiroshi, Hara
openaire   +2 more sources

Improving allogeneic stem cell transplantation in myelofibrosis

International Journal of Hematology, 2022
In this review, we will outline dimensions in which outcome of patients with myelofibrosis undergoing curative treatment can be optimized: patient selection, transplant procedure, and posttransplant prevention or treatment of relapse. For patient selection, fortunately, as with several other hematologic malignancies, the management of patients with ...
Nico, Gagelmann, Nicolaus, Kröger
openaire   +2 more sources